• FILTER YOUR SEARCH
    Speciality:
    More Specialities

    • ESO Highlights

    Stroke
    Johanna Ospel, ESOC 2021: Predictors and Clinical Impact of Infarct Progression Rate in the ESCAPE-NA1 Trial

    We had the pleasure of meeting up with Dr Johanna Ospel (University Hospital, Basel, Switzerland) to discuss the findings from the ESCAPE-NA1 Trial. The abstract entitled “Predictors and Clinical Impact of Infarct Progression Rate in the ESCAPE-NA1 Trial” was presented at the 7th European Stroke Conference, 1-3 September 2021. Questions: Why is it so important […]

    Stroke
    Michael Hill, ESOC 2021: Nerinetide for the treatment of Acute Ischaemic Stroke – ESCAPE-NA1 Trial Results

    We had the pleasure of meeting up with Prof. Michael Hill (University of Calgary, Calgary, Canada) to discuss the use of nerinetide in the treatment of patients who had an acute ischaemic stroke, and the findings from the ESCAPE-NA1 trial. The session entitled “Nerinetide for LVO Neuroprotection: Fact or Fiction?” was presented at the 7th […]

    Stroke
    Hanne Christensen, Arlene Wilkie & Francesca Romana Pezzella: Stroke Action Plan for Europe (Part 1)

    In conjunction with the European Stroke Organisation (ESO), we had the pleasure of meeting with Prof. Hanne Christensen (Chair, Stroke Action Plan for Europe), Arlene Wilkie (Co-Chair, Stroke Action Plan for Europe), and Dr Francesca Romana Pezzella (Co-Chair, Stroke Action Plan for Europe) to discuss the Stroke Action Plan for Europe (SAP-E), a pan-European project, setting […]

    Stroke
    Hanne Christensen, Arlene Wilkie & Francesca Romana Pezzella: Stroke Action Plan for Europe (Part 2)

    In conjunction with the European Stroke Organisation (ESO), we had the pleasure of meeting with Prof. Hanne Christensen (Chair, Stroke Action Plan for Europe), Arlene Wilkie (Co-Chair, Stroke Action Plan for Europe), and Dr Francesca Romana Pezzella (Co-Chair, Stroke Action Plan for Europe) to discuss the Stroke Action Plan for Europe (SAP-E), a pan-European project, […]

    Stroke
    Arlene Wilkie, ESO-WSO 2020 – Stroke Action Plan for Europe

    We were delighted to have an opportunity to hear all about the Stroke Action Plan for Europe from Arlene Wilkie, Director General of the Stroke Alliance for Europe (SAFE). Related useful resources: Stroke Alliance for Europe (SAFE) Economic Impact of Stroke in Europe Questions What are the major challenges in stroke care across Europe and […]

    Stroke
    Jeffrey L Saver & Natan Bornstein, ESOC 2019 – ImpACT-24B

    Trial investigators Jeffrey L Saver and Natan Bornstein share results and insights from the Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window (ImpACT-24B; NCT00826059). The aim of this international, randomised, double-blind, sham-controlled, pivotal trial was to determine whether sphenopalatine ganglion stimulation 8-24 h after acute ischaemic stroke improved […]

    Stroke
    Nikola Sprigg, ESOC 2019 – TICH-2

    Nikola Sprigg, Principal Investigator of the Tranexamic acid for IntraCerebral Haemorrhage 2 (TICH-2) trial (ISRCTN93732214), which previously reported that tranexamic acid does not improve outcome in adults with stroke due to intracerebral haemorrhage despite reducing haematoma expansion, shares results and insights from one-year follow up data. Content produced in Milan, Italy and shared with kind authorisation […]

    Stroke
    Masatoshi Koga & Manabu Inoue, ESOC 2019 – THAWS trial

    Trial investigators Masatoshi Koga and Manabu Inoue discuss results from THAWS (NCT02002325), an investigator-initiated Japanese multicentre randomised controlled clinical trial designed to clarify the efficacy and safety of MRI-based intravenous thrombolysis with alteplase for patients with acute wake-up ischaemic stroke and those having acute ischaemic stroke with unknown time of symptom onset. Content produced in […]

    Stroke
    Tom Moullaali, ESOC 2019 – Pooled individual patient data analyses of the INTERACT2 and ATACH-II trials

    Tom Moullaali discusses results of pooled individual patient data analyses of the INTERACT2 (NCT00716079) and ATACH-II (NCT01176565) trials, the two largest studies of blood pressure control in acute intracerebral haemorrhage. The aim of the meta-analysis was to ascertain whether systolic blood pressure parameters are associated with better clinical outcomes. Content produced in Milan, Italy and […]

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72